|
|
|
市場調查報告書
經由鼻子服用藥物的全球市場
Intranasal Drug Delivery
|
經由鼻子服用藥物的全球市場 是由出版商Global Industry Analysts, Inc.在2011年01月所出版的。
這份英文市場調查報告書包含Pages: 378 價格從美金4500起跳。
本報告書內容包括:全球的經由鼻子服用的藥物市場的調查分析、產業的概要、市場動態、技術趨勢、經鼻藥的概要、主要研究開發、最近的技術發展、最近的產業活動、主要企業的概要、市場分析等彙整、內容綱要摘記如下:
第1章 介紹、調查方法、產品的定義
第2章 產業的概要
- 給藥
- 經由鼻子服用的藥物的設備和機器
- 既存/最新的經由鼻子服用的藥物設備
- 美國的經鼻噴液設備市場
- GSK切斷Flonase的專利剝奪Merck的佔有率
第3章 市場的動態
第4章 技術動向
- 經由鼻子服用的藥物の概要
- 經鼻藥：處方藥和市售藥
- 粉末經鼻藥和噴液經鼻藥
- 經由鼻子服用的藥物設備
- 經由鼻子服用的藥物和其他服用藥物方法
- 經由鼻子服用的藥物的界線
- 過敏
第5章 經由鼻子服用藥物的概要
- 過敏用經鼻藥
- 停經後骨質疏鬆症用經鼻藥
- 經鼻疼痛管理藥
- 經鼻疫苗
- 性功能障礙用經鼻藥
- 維他命B12缺乏症治療用經鼻噴液
- 禁煙治療用經鼻噴液
第6章 主要研究開發計劃
第7章 最近的技術發展
第8章 產品的革新和引進
第9章 最近的產品革新和引進
第10章 最近的產業活動
第11章 最近的企業活動
第12章 全球的主要企業
第13章 市場分析
競爭企業介紹
Abstract
This report analyzes the US market for Intranasal Drug Delivery in US$ Million
by the following Therapeutic Areas: Allergic Infections, Analgesics,
Osteoporosis, and Vaccinations. Annual estimates and forecasts are provided
for the period 2007 through 2015. Also, a six-year historic analysis is
provided for this market. The report profiles 75 companies including many key
and niche players such as Aegis Therapeutics LLC, Alza Corporation,
AptarGroup, Inc., Archimedes Pharma Limited, AstraZeneca Plc, MedImmune, Inc.,
Bayer Consumer Care, Bespak Plc, GlaxoSmithKline Plc, Ikano Therapeutics Inc.,
Javelin Pharmaceuticals, Inc., Kurve Technology, Inc., Marina Biotech, Inc.,
Merck & Co., Inc., Novartis AG, OptiNose AS, Pfizer, Inc., Rexam Plc,
Sanofi-Aventis S.A., and Unigene Laboratories, Inc. Market data and analytics
are derived from primary and secondary research. Company profiles are mostly
extracted from URL research and reported select online sources.
Table of Contents
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
2. INDUSTRY OVERVIEW
- Drug Delivery: A Quick Primer
- The Nose: An Attractive Avenue to Cross the Blood Brain Barrier
- Self-Administration of Drugs Brings Intranasal Drug Delivery Into the
Spotlight
- Research & Technology Opens Up New Therapeutic Areas for Nasal Drug
Delivery
- Product Developments in the US Intranasal Drug Delivery Market: 2007
- R&D: Critical to the Commercialization of Intranasal Drug Delivery
- Tight Junction Biology: A Key Speed Breaker in Commercialization
- RNA Interference (RNAi): A Tool to Manipulate Tight Junctions
- Why Is Nasal Drug Delivery the Theme of All Drug Delivery Research
Projects?
- Nasal Drug Delivery Devices & Equipment
- Preservative Free Systems (P.F.S.)
- Traditional Vs. Advanced Intranasal Drug Delivery Devices
- Pitfalls Of Traditional Delivery Devices
- The Promise of New Advanced Delivery Devices
- Bi-Directional Nasal Drug Delivery: A Technology With a Huge Potential
- Benefits of Bi-Directional Delivery Authenticated Through Research
Studies
- Market for Nasal Spray Devices in the US
- GSK Looses Share to Merck, Following Patent Expiry of Flonase
- Table 1: US Intra-Nasal Steroid Market for AllergicRhinitis: Sales
of Leading Nasal Formulations for2008 (includes corresponding Graph/Chart)
- Table 2: The US Nasal Drug Delivery Market for Allergic Rhinitis:
Sales Of Top Four Nasal Steroid Formulationsfor The Year 2005 (In US$
Million) (includescorresponding Graph/Chart)
3. MARKET DYNAMICS
- Innovation in Drug Delivery: A Talisman For Success
- Controlled Release Technology Is the Buzz Word
- Target-Specific Delivery Devices: Of Critical Value
- Safety and Cost: Primary Growth Drivers
- Preservatives Losing Sheen in Nasal Spray Formulations
- Multi-Dose Containers Evolve to Offer Resistance Against Microbial
Contamination
- Bioavailability: An Important Facet of Intranasal Drug Delivery
- Chemical Modification
- Transient Modification & Limited Enzymatic Activity
- Bioavailability of Large Molecules
- Bio-Adhesive Polymers: Useful in Increasing Drug Absorption
- Mixed Opinions on Efficiency of Calcitonin Nasal Spray
- Nasal Preparations Gaining Foothold in Cough and Allergic Categories
- Patent Expiries Impact Market Opportunities
4. TECHNOLOGY OVERVIEW
- Intranasal Drug Delivery: A Descriptive Exposition
- Nasal Physiology
- Challenges Involved In Formulating Nasal Drugs
- The Importance of Bioadhesion
- Challenges Involved In Designing Devices
- Overview of the Traditional Drug Administration Routes, Molecular
Weight Capabilities, and Dosage Range
- Intranasal Drugs - Prescription (Rx) and Over-the- Counter (OTC)
- Differences Between Systemic Delivery and Local Effects
- Nasal Powders Vs Sprays
- Nasal Drug Delivery Devices
- Types of Drug Delivery Devices
- Droppers
- Sprays
- Aerosol Containers/Inhalers
- Pumps
- Nasal Aspirator
- Intranasal Drug Delivery Vis-à-vis Other Delivery Techniques
- Table 3: US Market for Intranasal Drugs: Percentageshare of Topical
and Systemic Drugs by value forthe Years 2006 and 2015
- Limitations of Intranasal Drug Delivery
- Allergy
- Definition
- Symptoms
- Allergic Rhinitis
- Nasal Allergies
- Table 4: US Market for Nasal Sprays: Top Five NasalSprays for
Cough, Cold, Sinus and Allergy Ranked byDollar Retail Sales for the Year
Ended January2008 (In US $ Million) (includes corresponding Graph/Chart)
- Table 5: US Market for Nasal Sprays, Drops andInhalers: Top 10
Brands Ranked by Dollar SalesThrough Drug Stores for the Year Ended
January2008 (In US $ Million) (includes corresponding Graph/Chart)
- Table 6: US Market for Nasal Sprays, Drops andInhalers: Top 10
Brands Ranked by Unit SalesThrough Drug Stores for the Year Ended
January2008 (In Thousand Units) (includescorresponding Graph/Chart)
5. NASAL DRUGS: AN OVERVIEW
- Nasal Drugs for Allergies
- Corticosteroid Nasal Sprays
- Flonase
- Patanase
- Beconase
- Other Nasal Corticosteroid Drugs
- Antihistamine Nasal Sprays
- Astelin Nasal Spray
- Otrivin Nasal Spray
- Livostin Nasal Spray
- Other Nasal Antihistamine Drugs
- Select Brands of Allergy Relievers
- Nasal Drugs for Postmenopausal Osteoporosis
- Calcitonin-Salmon Nasal Spray
- Miacalcin Nasal Spray
- Fortical® Nasal Spray
- Intranasal Pain Management Drugs
- Stadol Nasal Spray
- Rylomine
- Imitrex
- Migranal
- Zolmitriptan Nasal Spray
- Intranasal Analgesics For Treating Migraine
- Select Intranasal Pain Management Products in Development
- Intranasal Vaccination
- Process of Intranasal Immunization
- Market Drivers
- "LAIV" Nasal Spray Flu Vaccine
- FluMist® Vaccine From MedImmune
- Intranasal Drugs for Sexual Dysfunction
- Table 7: US Market for Intranasal Sexual DysfunctionDrugs: Revenues
for the Years 2010 through 2012in US$ Million (includes corresponding
Graph/Chart)
- Nasal Spray for Treating Vitamin B12 Deficiency
- Nasal Spray for Aiding Smoking Cessation
- Intranasal Drugs in Pipeline: 2008 and 2009
- Other Intranasal Drugs in Pipeline
6. SELECT RESEARCH & DEVELOPMENT INITIATIVES
- Nastech Enrolls 551 Patients for Phase 2 Trials of PYY3-36 Nasal Spray
- Archimedes Pharma Commences Phase III Trials for NasalFent®
- Archimedes Presents New Clinical Data on NasalFent®
- LigoCyte Commences Clinical Trials for Intranasal Norovirus Vaccine
- Javelin Pharmaceuticals Reveals Phase 2 Study Results for PMI-100/150
- Javelin Pharmaceuticals Commences Phase III studies for PMI-150
- Nastech Commences Phase 2 Trials for Insulin Nasal Spray
- ACAAI Reveals Results for Trials of Nasacort® AQ Nasal Spray in
Children
- TGAR01H from Fabre Kramer
- Aegis Therapeutics Completes First Human Clinical Study on Intravail®
- Nastech Pharmaceutical Presents Clinical Test Results on Parathyroid
Hormone
- Zolmitriptan Promises Relief for Cluster Headaches
- CAIV-T: More Effective than Injectable Influenza Vaccines
- Intranasal Therapeutics Conducts Study on Midazolam
- Nastech Announces Phase I Results of Insulin Nasal Spray
- Archimedes Completes Phase II Trials of NASALFENT
- Intranasal Corticosteroid Proven Effective for Treating Allergic Rhinitis
- Aegis Files DMF for Intravail
- Nasal Sprays: A New-Generation Treatment for Gynecological Problems
- Aegis Therapeutics Conducts Feasibility Study on Drug Delivery Technology
- GelVac Powder Delivery System Completes Phase I Clinical Trial
- OptiNose Develops Intranasal Delivery System for Osteoporosis
- Nastech Initiates Dose Ranging Study of PYY(3-36)
- Valois Develops New Nasal Dispensing System
- Rigel Pharmaceuticals to Initiate R112 Phase II Clinical Trial
- MedPointe Pharmaceuticals Demonstrates ACT1 Study Results on ASTELIN®
- Bentley Pharmaceuticals Demonstrates Clinical Trial Results of its Intra
Nasal Insulin Spray
7. RECENT TECHNOLOGICAL DEVELOPMENTS
- New-Generation Technologies and Devices
- ViaNase from Kurve Technology
- A New Product from OptiNose
- Nastech's "Tight Junction Biology" Research Program
- ChiSys™ Nasal Delivery Technology from Archimedes
8. PRODUCT INNOVATIONS/INTRODUCTIONS
- TheraBiogen to Introduce TheraMax Cold & Flu Nasal Spray
- Sinus Dynamics™ Unveils NasaTouch™ Nasal Delivery Device
- 3M Drug Delivery Systems Introduces Nasal MDI
- MeadWestvaco Introduces Preservative-Free Nasal Pumps
- GlaxoSmithKline Introduces Avamys Nasal Spray
9. PRODUCT INNOVATIONS/INTRODUCTIONS IN THE RECENT PAST- A PERSPECTIVE BUILDER
- Aegis Therapeutics Develops ProTek™
- Heel Launches Luffeel® in the US
- Archimedes to Introduce Intranasal Formulation of Human Growth Hormone
- Sinofresh Launches SinoFresh™ Nasal & Sinus Care
- PARI Respiratory Launches Nasal Drug Delivery Program
- OptiNose to Develop New Range of Intranasal Products
- OptiNose and Cambridge Consultants to Develop Advanced Nasal Delivery
Device
- Kurve Technology Develops ViaNase ID™
- Upsher-Smith Introduces Fortical® Nasal Spray
- Schering-Plough Launches New Formulation of NASONEX®
- AstraZeneca Unveils Rhinocort Aqua in the US
10. RECENT INDUSTRY ACTIVITY
- Upsher-Smith Acquires ITI-111 from Ikano Therapeutics
- Hospira Acquires Javelin Pharmaceuticals
- Archimedes Pharma Receives Approval for PecFent Nasal Spray
- Cypress Bioscience Obtains Patent Rights for Carbetocin Therapy
- MDRNA, Inc. Announces Change of Name
- Prosonix Inks Product Co-Development and Licensing with Trimel Biopharma
- Serenity Pharmaceuticals and Allergan Sign Agreement
- Ethicon Acquires Acclarent
- Ikano's Midazolam Obtains Orphan Drug Designation
- FDA Issues Not-Approvable Letter for Nastech's Generic Calcitonin-Salmon
- Trimel BioPharma Acquires Direct Haler
- Lupin Takes Over AllerNaze™ Rights from Collegium Pharmaceutical
- Nanotherapeutics Purchases DelSite Assets
- Schering-Plough Merges with Merck
- Valois Pharma and Nycomed Launch Spray Pump for Fentanyl
- Phylogica and Aegis Therapeutics Collaborate
- Intranasal Therapeutics is Now Ikano Therapeutics
- FDA Clears Use of New Clone in Calcitonin Production of Unigene
- Zelos Therapeutics Collaborates with Aegis Therapeutics
- ImmuneRegen BioSciences Partners with LRRI
- Avamys™ Nasal Spray Receives Approval in Europe
- PMI-150 Receives Canadian Patent
11. CORPORATE ACTIVITY IN THE RECENT PAST-A PERSPECTIVE BUILDER
- Javelin Releases Phase III Data of Rylomine Intranasal Morphine
- FDA Recommends Supplemental Study for Javelin's PMI-150
- Palatin Re-Acquires Bremelanotide Rights from King Pharma
- USFDA Approves FluMist® for Young Children
- USFDA Approves Veramyst Nasal Spray for Individuals Aged Two Years and
Above
- Kurve Technology Inks Agreement with Schering-Plough
- MedImmune Clarifies FDA Observations
- FluMist(R) Receives FDA Approval for Refrigerated Formulation
- Nastech Regains Rights for PTH1-34 Nasal Spray
- NASONEX(R) Receives Ease-of-Use Commendation from Arthritis Foundation
- Aegis Therapeutics Establishes Cedar Therapeutics Inc.
- EMEA Provides Encouraging Feedback for Avamys™ Nasal Spray
- Kurve Technologies Introduces Blog on Nasal Drug Delivery
- Accentia Extends Agreement with Mayo Foundation
- Nastech Signs Development and License Agreement with Amylin
- MedImmune's FluMist Plant Gets FDA Approval
- ShinNippon Subsidiaries Sign Licensing Agreement with Tokai Pharmaceuticals
- MeadWestvaco Acquires Saint-Gobain Calmar
- Merck Terminates PYY3-36 Partnership with Nastech
- Inspire Signs Licensing Agreement with Boehringer Ingelheim
- P&G Partners with Nastech to Develop PTH(1-34)
- Unigene Laboratories Signs Distribution Agreement with Tzamal Bio Pharma
- GlaxoSmithKline Seeks Marketing Approval for Fluticasone Furoate in the US
and Europe
- Kurve Technology Relocates Corporate Headquarters
- Kurve Inks an Agreement with DARA BioSciences
- Kurve Enters into a Development Agreement with Schering-Plough
- Altana Submits NDS for Approval of Ciclesonide Nasal Spray in Canada
- Altana Pharma AG Receives FDA Approval for Pediatric Use of Omnaris
- Intranasal Therapeutics Inc. Receives Financial Funding
- FDA Completes Pre-Approval Inspections at Nastech's Washington Facility
- Kos Signs Exclusive License Agreement with SkyePharma
- Bentley Signs Agreement with Biocon
- Intranasal Therapeutics Files Patent Application for Synthetic THC
- Ionix Pharmaceuticals in Collaboration with Reckitt Benckiser for Drug
Development
- University of Kentucky Receives Patent for new Intranasal Device
- Intranasal Technology Extends Collaboration with Aegis Therapeutics
- Accentia Biopharmaceuticals Signs License Agreement with Collegium
Pharmaceuticals
- Aegis Therapeutics Extends License Agreement with Intranasal Technologies
- Bentley Pharmaceuticals Signs Agreement with Dong Sung Pharmaceuticals
- Unigene Gets FDA Approval for Fortical Calcitonin- Salmon Nasal Spray
- OptiNose Signs Collaborative Agreement with MedPharm
- West Pharmaceutical Divests Drug Delivery Business to Archimedes Pharma
- Nastech Pharmaceutical Receives FDA Approval for Nascobal Nasal Spray
- Par and Nastech Sign Licensing Agreement
- Aegis Therapeutics Signs Licensing Agreement with University of Alabama
- ITI Receives a Patent for Sedation Inducing Nasal Drug
- Inyx Bags Order from Australian OTC Drug Company
12. FOCUS ON SELECT GLOBAL PLAYERS
- Aegis Therapeutics LLC (USA)
- Alza Corporation (USA)
- AptarGroup, Inc. (USA)
- Archimedes Pharma Limited. (UK)
- AstraZeneca Plc. (UK)
- Bayer Consumer Care (USA)
- Bespak Plc. (UK)
- GlaxoSmithKline Plc (UK)
- Ikano Therapeutics Inc. (USA)
- Javelin Pharmaceuticals, Inc. (USA)
- Kurve Technology, Inc. (USA)
- Marina Biotech, Inc. (USA)
- Merck & Co., Inc. (USA)
- Novartis AG (Switzerland)
- OptiNose AS (Norway)
- Pfizer, Inc. (USA)
- Rexam Plc (UK)
- Sanofi-Aventis S.A. (France)
- Unigene Laboratories, Inc. (USA)
13. MARKET ANALYTICS
- Table 8: US Recent Past, Current & Future Analysis for Intranasal
Drug Delivery by Therapeutic Area - Allergic Infections, Analgesics,
Osteoporosis, and VaccinationsMarkets Independently Analyzed by Annual
SalesFigures in US$ Million for Years 2007 through 2015(includes corresponding
Graph/Chart)
- Table 9: US Historic Review for Intranasal Drug Deliveryby Therapeutic
Area - Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets
IndependentlyAnalyzed by Annual Sales Figures in US$ Millionfor Years 2000
through 2006 (includescorresponding Graph/Chart)
- Table 10: US 11-Year Perspective for Intranasal DrugDelivery by
Therapeutic Area -Percentage Breakdownof Values Sales for Allergic Infections,
Analgesics,Osteoporosis, and Vaccinations for Years 2005, 2010 &2015
(includes corresponding Graph/Chart)
COMPETITIVE LANDSCAPE
|
 |
